NSECYFRA21―1与FIB联合检测对非小细胞肺癌患者临床意义.docVIP

NSECYFRA21―1与FIB联合检测对非小细胞肺癌患者临床意义 　　[摘要] 目的 探讨神经元特异性烯醇化酶（neuronspecific enolase，NSE）、细胞角蛋白19 片段21-1（Cytokeratin 19 fragment 21-1，CYFRA21-1）和纤维蛋白原（fibrinogen，FIB）联合检测在非小细胞肺癌（NSCLC）患者手术治疗前后和分期中的变化及临床意义。 方法 选取65例NSCLC作为研究对象（NSCLC组），同时选取30例肺部良性肿瘤患者（良性病变组）及30例同期体检健康者（健康对照组）为对照组，分别检测各组空腹及术后血清NSE和CYFRA21-1及FIB水平。 结果 NSCLC组NSE、CYFRA21-1及FIB水平均显著高于肺部良性病变组及健康对照组（P0.05），且水平与其临床分期呈正相关（r=0.621，0.563，0.445，P均0.05），其分期Ⅲ～Ⅳ期患者三项水平明显高于Ⅰ～Ⅱ期患者（P0.05）；术后4 周，NSCLC组三项水平均明显低于术前（P0.05）。 结论 NSE、CYFRA21-1及FIB水平在NSCLC手术前后有明显变化，且与临床分期有关，三项联合检测可作为NSCLC治疗评价及疾病监测、预后的指标。 　　[关键词] 非小细胞肺癌；神经元特异性烯醇化酶；细胞角蛋白19 片段21-1；纤维蛋白原 　　[中图分类号] R541.5 [文献标识码] A [文章编号] 1673-9701（2017）35-0029-03 　　[Abstract] Objective To investigate the changes of the combination detection of neuronspecific enolase NSE， Cytokeratin 19 fragment 21-1 （CYFRA21-1） and fibrinogen （FIB） in non-small cell lung cancer （NSCLC） patients before and after surgical treatment and during staging and their clinical significance. Methods Totally 65 patients with NSCLC were enrolled in this study （NSCLC group）. 30 patients with benign lung disease （benign lesions group） and 30 healthy controls （healthy control group） in the same period were selected as the control group. The fasting and postoperative serum NSE， CYFRA21-1 and FIB levels were detected respectively. Results The levels of NSE， CYFRA21-1 and FIB in NSCLC group were significantly higher than those in benign lung group and healthy control group（P0.05）， and the levels were positively correlated with their clinical stages（r=0.621， 0.563， 0.445， P0.05）. The three levels of patients with stage Ⅲ-Ⅳ were significantly higher than those of patients with stageⅠ-Ⅱ（P0.05）. At 4 weeks after surgery， all three levels of NSCLC group were significantly lower than those before operation（P0.05）. Conclusion The levels of NSE， CYFRA21-1 and FIB in NSCLC patients have significant changes before and after surgery， and are related to the clinical stage. The three combined tests can be used as indexes for NSC